Molecular predictors of response to zanubrutinib. Kaplan-Meier survival curves showing progression-free survival according to presence or absence of somatic mutations of (A) MYD88 or TNFAIP3 (B) KMT2D, (C) NOTCH1 or NOTCH2. Median follow-up: 11.1 months (2.76-16.80). ∗includes one COVID-19-related death.